ReviewCurrent oncology reports2013
Incorporation of prognostic and predictive factors into glioma clinical trials.
Review in Current oncology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic role of microRNA-21 expression in gliomas: a meta-analysis.Journal of neuro-oncology · 2016Pooled it
- Review
- Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.International journal of molecular medicine · 2022Article
- Examining the Landscape of Prognostic Factors and Clinical Outcomes for Cancer Control.Current oncology (Toronto, Ont.) · 2021Article
- Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide.Frontiers in oncology · 2018Article
- Clinical relevance of lysyl oxidase-like 2 and functional mechanisms in glioma.OncoTargets and therapy · 2018Article
- miRNA‑1271 inhibits cell proliferation in neuroglioma by targeting fibronectin 1.Molecular medicine reports · 2017Article
- Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Journal of personalized medicine · 2017Review
- Silencing of CtBP1 suppresses the migration in human glioma cells.Journal of molecular histology · 2016Article
- Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Prognostic value of long noncoding RNA MALAT1 in digestive system malignancies.International journal of clinical and experimental medicine · 2015Article
- Article
- Decreased expression of miR-378 correlates with tumor invasiveness and poor prognosis of patients with glioma.International journal of clinical and experimental pathology · 2015Article
- Combined detection of Gab1 and Gab2 expression predicts clinical outcome of patients with glioma.Medical oncology (Northwood, London, England) · 2014Article
- Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.Pharmacogenomics and personalized medicine · 2014Review
- Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Frontiers in oncology · 2014Review
- MicroRNA-21 expression is associated with overall survival in patients with glioma.Diagnostic pathology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Treatment of brain tumors is increasingly informed by biomarkers that predict patient prognosis and response to therapy. While this progress represents a great opportunity for the field of neuro-oncology, it also presents significant challenges. Biomarkers are not straightforward to identify, and previously used clinical trial paradigms are poorly suited to the task of identifying treatments effective only in selected subsets of patients. Unless investigators adapt new tools and procedures that better account for the biological diversity of gliomas, future clinical trials run the dual risk of missing important treatment effects and exposing patients to interventions destined to prove ineffective for their tumors. In this article, we will review the progress made in the past decade with respect to biomarkers in neuro-oncology, address barriers to ongoing progress, and discuss clinical trial designs that may prove useful in moving neuro-oncology fully into the era of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.